Association of docosahexaenoic acid supplementation with Alzheimer disease stage in Apolipoprotein e ϵ4 carriers: A review

JAMA Neurology

Volumn 74, Issue 3, 2017, Pages 339-347

  Yassine, Hussein N ^a   Braskie, Meredith N ^a   Mack, Wendy J ^a   Castor, Katherine J ^b   Fonteh, Alfred N ^b   Schneider, Lon S ^a   Harrington, Michael G ^b   Chui, Helena C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; DOCOSAHEXAENOIC ACID; OMEGA 3 FATTY ACID;

ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; BIOAVAILABILITY; CEREBRAL AMYLOIDOSIS; COGNITION; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; GENOTYPE; HUMAN; LIPOLYSIS; META ANALYSIS (TOPIC); NERVE DEGENERATION; NEUROIMAGING; NEUROPROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STAGING; SYSTEMATIC REVIEW (TOPIC); GENETICS;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; DOCOSAHEXAENOIC ACIDS; HUMANS;

EID: 85017619831     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.4899     Document Type: Review

References (75)

1. Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al; European Alzheimer's Disease Initiative (EADI); Genetic and Environmental Risk in Alzheimer's Disease; Alzheimer's Disease Genetic Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458.
2. Corder EH, Saunders AM, StrittmatterWJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
3. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3 (89):89ra57.
4. Friedman G, Froom P, Sazbon L, et al. Apolipoprotein E-ϵ4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 1999;52(2):244-248.
5. Egensperger R, Kosel S, von Eitzen U, Graeber MB. Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol. 1998;8(3):439-447.
6. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. JAMA Neurol. 2013;70(4):440-444.
7. Rapoport SI, Igarashi M. Can the rat liver maintain normal brain DHA metabolism in the absence of dietary DHA?. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2-3):119-123.
8. Grimm MO, Kuchenbecker J, Grosgen S, et al. Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms. J Biol Chem. 2011;286(16):14028-14039.
9. Hooijmans CR, Rutters F, Dederen PJ, et al. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical western diet (TWD). Neurobiol Dis. 2007;28(1):16-29.
10. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids. 1991;26(6): 421-425.
11. Hooijmans CR, Pasker-de Jong PC, de Vries RB, Ritskes-Hoitinga M. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis. 2012;28(1):191-209.
12. Zhang Y, Chen J, Qiu J, Li Y, Wang J, Jiao J. Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: A dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr. 2016;103(2):330-340.
13. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA. 2010;304(17):1903-1911.
14. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol. 2006;63(10): 1402-1408.
15. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology. 2008;71(6):430-438.
16. Chiu C-C, Su K-P, Cheng T-C, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1538-1544.
17. Lee LK, Shahar S, Chin A-V, Yusoff NAM. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): A 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2013;225(3):605-612.
18. Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: A 6-month randomised controlled trial. Br J Nutr. 2012;107(11):1682-1693.
19. StonehouseW, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: A randomized controlled trial. Am J Clin Nutr. 2013;97(5):1134-1143.
20. Kulzow N, Witte AV, Kerti L, et al. Impact of omega-3 fatty acid supplementation on memory functions in healthy older adults. J Alzheimers Dis. 2016;51(3):713-725.
21. Benton D, Donohoe RT, Clayton DE, Long SJ. Supplementation with DHA and the psychological functioning of young adults. Br J Nutr. 2013;109(1): 155-161.
22. Jackson PA, DearyME, Reay JL, Scholey AB, Kennedy DO. No effect of 12 weeks' supplementation with 1 g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18-35 years. Br J Nutr. 2012;107(8): 1232-1243.
23. Yurko-Mauro K, McCarthy D, Rom D, et al; MIDAS Investigators. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010;6(6): 456-464.
24. Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci. 2008;11(2):75-83.
25. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y ω-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: A randomized, double-blind, controlled trial. Am J Clin Nutr. 2010;91(6):1725-1732.
26. Geleijnse JM, Giltay EJ, Kromhout D. Effects of ω-3 fatty acids on cognitive decline: A randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimers Dement. 2012;8(4):278-287.
27. Sydenham E, Dangour AD, LimW-S. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012; (6):CD005379.
28. Yurko-Mauro K, Alexander DD, Van ElswykME. Docosahexaenoic acid and adult memory: A systematic review and meta-analysis. PLoS One. 2015;10(3):e0120391.
29. Cao D, Kevala K, Kim J, et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem. 2009;111(2): 510-521.
30. Salem N Jr, Moriguchi T, Greiner RS, et al. Alterations in brain function after loss of docosahexaenoate due to dietary restriction of n-3 fatty acids. J Mol Neurosci. 2001;16(2-3):299-307.
31. Kariv-Inbal Z, Yacobson S, Berkecz R, et al. The isoform-specific pathological effects of APOE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28 (3):667-683.
32. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE ϵ4. Neurology. 2005;65(9):1409-1414.
33. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia: The Three-City cohort study. Neurology. 2007;69(20): 1921-1930.
34. Whalley LJ, Deary IJ, Starr JM, et al. ω-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: An observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87(2):449-454.
35. Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR; Alzheimer's Disease Neuroimaging Initiative. Association of fish oil supplement use with preservation of brain volume and cognitive function. Alzheimers Dement. 2015;11(2):226-235.
36. Laitinen MH, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. Dement Geriatr Cogn Disord. 2006;22(1):99-107.
37. Morris MC, Brockman J, Schneider JA, et al. Association of seafood consumption, brain mercury level, and APOE ϵ4 status with brain neuropathology in older adults. JAMA. 2016;315(5): 489-497.
38. Samieri C, Feart C, Proust-Lima C, et al. ω-3 Fatty acids and cognitive decline: Modulation by APOEϵ4 allele and depression. Neurobiol Aging. 2011;32(12):2317. e13-2317. e22.
39. Vellas B, Voisin T, Dufouil C, et al. MAPT (Multi-Domain Alzheimer's Prevention Trial): Clinical biomarkers, results and lessons for the future [abstract OC33]. J Prev Alzheimers Dis. 2015;2(4):292.
40. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma ω-3 fatty acids and the risk of cognitive decline in older adults: The Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2007;85(4):1103-1111.
41. Kroger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of dementia: The Canadian Study of Health and Aging. Am J Clin Nutr. 2009;90(1):184-192.
42. Ronnemaa E, Zethelius B, Vessby B, Lannfelt L, Byberg L, Kilander L. Serum fatty-acid composition and the risk of Alzheimer's disease: A longitudinal population-based study. Eur J Clin Nutr. 2012;66(8): 885-890.
43. Yassine HN, Feng Q, Azizkhanian I, et al. Association of serum docosahexaenoic acid with cerebral amyloidosis. JAMA Neurol. 2016;73(10): 1208-1216.
44. Yassine HN, Rawat V, MackWJ, et al. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016;8:25.
45. Vandal M, AlataW, Tremblay C, et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem. 2014;129(3):516-526.
46. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;50(suppl):S183-S188.
47. Polozova A, Salem N Jr. Role of liver and plasma lipoproteins in selective transport of ω-3 fatty acids to tissues: A comparative study of 14C-DHA and 3H-oleic acid tracers. J Mol Neurosci. 2007;33(1): 56-66.
48. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990;31(8):1503-1511.
49. Chouinard-Watkins R, Rioux-Perreault C, Fortier M, et al. Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the APOE ϵ4 allele. Br J Nutr. 2013;110(10):1751-1759.
50. Calon F. Omega-3 polyunsaturated fatty acids in Alzheimer's disease: Key questions and partial answers. Curr Alzheimer Res. 2011;8(5):470-478.
51. HallidayMR, Pomara N, Sagare AP, MackWJ, Frangione B, Zlokovic BV. Relationship between cyclophilin A levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol. 2013;70(9):1198-1200.
52. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014;509(7501): 503-506.
53. Fu Y, Zhao J, Atagi Y, et al. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener. 2016;11(1):37.
54. Boehm-Cagan A, Michaelson DM. Reversal of APOE4-driven brain pathology and behavioral deficits by bexarotene. J Neurosci. 2014;34(21): 7293-7301.
55. Yassine HN, Feng Q, Chiang J, et al. ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer's disease. J Am Heart Assoc. 2016;5(2):e002886.
56. Klosinski LP, Yao J, Yin F, et al. White matter lipids as a ketogenic fuel supply in aging female brain: Implications for Alzheimer's disease. EBioMedicine. 2015;2(12):1888-1904.
57. Reich EE, MarkesberyWR, Roberts LJ II, Swift LL, Morrow JD, Montine TJ. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol. 2001;158(1):293-297.
58. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55(5):697-711.
59. Sanchez-Mejia RO, Newman JW, Toh S, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008;11(11):1311-1318.
60. Fonteh AN, Chiang J, Cipolla M, et al. Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease. J Lipid Res. 2013;54(10):2884-2897.
61. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE ϵ4 effect. N Engl J Med. 2009;361(3):255-263.
62. Vellas B, Voisin T, Dufouil CI, et al. MAPT study: A multidomain approach for preventing Alzheimer's disease: Design and baseline data. J Prev Alzheimers Dis. 2014;1(1):13-22.
63. Umhau JC, ZhouW, Carson RE, et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res. 2009;50(7):1259-1268.
64. Umhau JC, ZhouW, Thada S, et al. Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: A positron emission tomography study corrected for cerebral atrophy. PLoS One. 2013;8(10):e75333.
65. Morris JC, Roe CM, Xiong C, et al. APOE predicts Aβ but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1): 122-131.
66. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101(1):284-289.
67. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001;98(19):10966-10971.
68. Pifferi F, Dorieux O, Castellano CA, et al. Long-chain ω-3 PUFAs from fish oil enhance resting state brain glucose utilization and reduce anxiety in an adult nonhuman primate, the grey mouse lemur. J Lipid Res. 2015;56(8):1511-1518.
69. Sheline YI, Morris JC, Snyder AZ, et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci. 2010;30(50):17035-17040.
70. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101(13):4637-4642.
71. Chang PK, Khatchadourian A, McKinney RA, Maysinger D. Docosahexaenoic acid (DHA): A modulator of microglia activity and dendritic spine morphology. J Neuroinflammation. 2015;12:34.
72. Thomas J, Thomas CJ, Radcliffe J, Itsiopoulos C. Omega-3 fatty acids in early prevention of inflammatory neurodegenerative disease: A focus on Alzheimer's disease. Biomed Res Int. 2015;2015: 172801.
73. Witte AV, Kerti L, Hermannstadter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. Cereb Cortex. 2014;24(11):3059-3068.
74. Liu DS, Pan XD, Zhang J, et al. APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Mol Neurodegener. 2015;10:7.
75. Burggren AC, Zeineh MM, Ekstrom AD, et al. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage. 2008;41 (4):1177-1183.